Your browser doesn't support javascript.
loading
High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors.
Kim, Nam Kyeong; Suh, Dong Hoon; Kim, Kidong; No, Jae Hong; Kim, Yong Beom; Kim, Minki; Cho, Young-Ho.
Afiliación
  • Kim NK; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • Suh DH; Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Kim K; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • No JH; Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Kim YB; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • Kim M; Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Cho YH; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
PLoS One ; 19(6): e0304704, 2024.
Article en En | MEDLINE | ID: mdl-38833451
ABSTRACT

OBJECTIVE:

To evaluate the diagnostic performance of circulating tumor cells (CTCs) using tapered-slit membrane filter (TSF)-based chipsets for the differential diagnosis of adnexal tumors.

METHODS:

A total of 230 women with indeterminate adnexal tumors were prospectively enrolled. The sensitivity, specificity, and accuracy of the CTC-detecting chipsets were analyzed according to postoperative pathological results and compared with those of cancer antigen (CA)-125 and imaging tests.

RESULTS:

Eighty-one (40.3%) benign tumors, 31 (15.4%) borderline tumors, and 89 (44.3%) ovarian cancers were pathologically confirmed. The sensitivity, specificity, and accuracy of CTC-detecting chipsets (75.3%, 58.0%, and 67.1%) for differentiating ovarian cancer from benign tumors were similar to CA-125 (78.7%, 53.1%, and 66.5%), but lower than CT/MRI (94.2%, 77.9%, and 86.5%). "CTC or CA125" showed increased sensitivity (91.0%) and "CTC and CA-125" revealed increased specificity (77.8%), comparable to CT/MRI. CTC detection rates in stage I/II and stage III/IV ovarian cancers were 69.6% and 81.4%, respectively. The sensitivity to detect high-grade serous (HGS) cancer from benign tumors (84.6%) was higher than that to detect non-HGS cancers (68.0%).

CONCLUSION:

Although the diagnostic performance of the TSF platform to differentiate between ovarian cancer and benign tumors did not yield significant results, the combination of CTC and CA-125 showed promising potential in the diagnostic accuracy of ovarian cancer.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antígeno Ca-125 / Células Neoplásicas Circulantes Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antígeno Ca-125 / Células Neoplásicas Circulantes Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos